The DSO and MSO model is the dominant mechanism through which private capital accesses the dental, medical, and veterinary markets. The model exists because most states prohibit lay entities from owning or operating licensed professional practices directly. The workaround is a bifurcated structure: a lay management company, the MSO or DSO, provides facilities, equipment, staffing, billing, technology, and administrative support to a separately owned professional entity under a long-term management services agreement. The professional entity, owned by licensed clinicians under a friendly PC or PLLC arrangement, holds the licenses and employs or contracts with the practitioners. The MSO captures the economics through management fees.
Every component of this structure carries legal risk that must be understood and managed at every stage of a transaction. The analysis below addresses twelve categories of structural, regulatory, and transactional issues that counsel must work through in any DSO, MSO, or healthcare platform acquisition. The framework applies to dental, medical, and veterinary contexts, with specific state variations identified throughout.
Corporate Practice of Medicine Doctrine: Origins, Public Policy Rationale, and Fee Splitting Prohibitions
The corporate practice of medicine doctrine is a judicially and legislatively developed body of law that prohibits lay entities, meaning non-licensed corporations, partnerships, and individuals, from employing licensed physicians, dentists, or other healthcare professionals to provide professional services, or from owning or controlling a professional practice. The doctrine emerged in American case law during the first half of the twentieth century as courts and legislatures responded to concerns that the commercialization of medicine would compromise the professional judgment that physician-patient relationships require.
The leading early case establishing CPOM doctrine principles is People v. Pacific Health Corporation, 82 Cal. App. 2d 236 (1947), in which the California Court of Appeal held that a lay corporation could not legally operate a medical clinic by employing licensed physicians, because doing so constituted the unlicensed practice of medicine by the corporation. The court's reasoning emphasized that licensed professional judgment cannot be delegated to a commercial entity whose obligations run to shareholders rather than patients, and that laypeople exercising authority over clinical decisions would compromise the independence that the medical licensing system is designed to protect.
The public policy rationale underlying CPOM doctrine operates on two levels. At the individual patient level, the concern is that a lay owner optimizing for commercial return will pressure clinicians to over-treat, under-treat, or prioritize revenue over clinical appropriateness. At the regulatory level, the concern is that the licensing framework, which holds individual practitioners personally accountable for clinical decisions, is undermined when those decisions are effectively controlled by an entity that faces no professional discipline and holds no license that can be revoked.
Fee splitting prohibitions exist alongside CPOM doctrine as a parallel regulatory framework. Fee splitting rules prohibit licensed professionals from sharing professional fees with unlicensed entities or individuals in exchange for referrals or as a condition of practice participation. The critical distinction is between a legitimate payment for services, such as a management fee paid to an MSO for genuine administrative and operational support, and an unlicensed fee share that compensates a lay party for arranging or directing clinical work. Most state medical and dental practice acts prohibit fee splitting categorically, and regulators apply the prohibition broadly to any percentage-based compensation arrangement that ties lay entity compensation to clinical revenue without adequate documentation of legitimate services rendered.
State-by-State CPOM Analysis: Strict Prohibition States, Permissive Jurisdictions, and Hybrid Frameworks
The corporate practice doctrine is not uniform across the United States. Each state has developed its own version of the prohibition through a combination of statute, regulation, and case law, and the practical implications for DSO and MSO structuring vary enormously by jurisdiction. Counsel advising on a multi-state healthcare platform must map each operating state independently rather than applying a single national framework.
The strictest CPOM jurisdictions for medical practice are California, New York, Illinois, Texas, New Jersey, and Oregon. California's prohibition is codified in Business and Professions Code Sections 2052 and 2400, which make it unlawful for any person or entity not licensed as a physician to practice medicine, and courts have applied these provisions broadly to invalidate arrangements where a lay entity exercises operational control over a medical group. New York's Education Law Section 6522 prohibits unlicensed practice of medicine, and Attorney General opinions have historically limited the ability of lay entities to participate in the economics of medical practice. Texas has a physician self-referral prohibition and CPOM case law that limits lay ownership, and New Jersey and Oregon have both demonstrated regulatory enforcement postures that make aggressive lay-owned structures difficult to sustain.
The dental and veterinary CPOM frameworks parallel the medical doctrine but are codified in separate practice acts. Dental practice acts in California, New York, and Illinois categorically prohibit lay ownership of dental practices, making the DSO friendly PC structure an operational necessity rather than a choice in those states. Veterinary practice acts in Oregon and New Jersey have been interpreted to prohibit lay ownership of veterinary practices, and enforcement actions in those states have targeted private equity-backed veterinary roll-ups that failed to maintain adequate professional entity separation.
Permissive jurisdictions include Arizona, which amended its professional corporation statutes to allow lay ownership of medical practices under specific conditions, and Florida, Michigan, Ohio, and Colorado, where MSO structures can be designed with broader lay participation without triggering categorical prohibition. These states generally still impose requirements around clinical independence, prohibit lay entities from directing clinical decisions, and require that licensing remain with the professional entity, but they do not categorically ban lay economic participation in the same way as the strict prohibition states. Hybrid states, including Washington and Georgia, impose intermediate restrictions: they permit MSO arrangements but scrutinize clinical control provisions carefully and require robust contractual protections for professional independence.
Friendly PC and PLLC Model Mechanics: Nominee Shareholder Agreements, Stock Transfer Restrictions, and Succession Planning
In states that prohibit lay ownership of professional practices, the DSO or MSO structure requires that all equity in the professional entity be held by licensed professionals. The practical solution is the friendly PC model: a licensed clinician, the nominee, holds legal title to the shares of the professional corporation or professional limited liability company, but the economic interest, control rights, and decision-making authority over non-clinical matters flow to the lay MSO through a network of interlocking contracts.
The nominee shareholder agreement is the foundation of the structure. It documents the nominee's agreement to hold shares on behalf of the MSO, the nominee's obligations to vote shares in accordance with the MSO's direction on non-clinical matters, and the nominee's agreement not to transfer shares without MSO consent. The agreement also establishes the economic terms under which the nominee is compensated for serving in the nominee role, typically a nominal annual fee separate from the nominee's clinical compensation, which is paid by the professional entity. A well-drafted nominee agreement separates the nominee's clinical employment terms from the nominee shareholder function clearly, to avoid any suggestion that the nominee's clinical employment is conditional on compliance with the shareholder arrangement.
The stock transfer restriction agreement, often called a restriction agreement or share pledge agreement, is a separate instrument that restricts the nominee's ability to transfer, pledge, or encumber the shares without the MSO's consent, and obligates the nominee to transfer the shares to a replacement nominee upon the occurrence of defined triggering events. Triggering events typically include the nominee's voluntary resignation from the nominee role, the nominee's termination of clinical employment, loss of professional licensure, death, disability, or bankruptcy. The restriction agreement should include an irrevocable proxy granting the MSO or its designated agent the authority to vote the shares and execute corporate documents on the nominee's behalf, so that the structural integrity of the professional entity is not dependent on the nominee's continued cooperation at any given moment.
Succession planning within the friendly PC structure requires maintaining a pipeline of pre-screened replacement nominees who have signed conditional nomination agreements. When a triggering event occurs, the MSO needs to install a replacement nominee without creating a period during which the professional entity operates without a properly qualified shareholder. The succession mechanism should also address tax implications: a transfer of shares from one nominee to another may constitute a taxable exchange depending on how the shares are characterized for tax purposes, and the nominee's estate may face estate tax considerations if death is the triggering event. Counsel should coordinate with tax advisors to ensure that the nominee agreement's tax provisions reflect the intended economic treatment of the arrangement and that any transfer is structured to minimize unnecessary tax friction.
MSO Management Services Agreement Structure: Fair Market Value Fees, Safe Harbor Principles, and OIG Guidance
The management services agreement is the contract through which the MSO provides services to the professional entity and receives its management fee. The MSA is also the document most likely to be scrutinized by regulators, plaintiffs' counsel, and counterparties seeking to challenge the validity of the structure. A well-drafted MSA must accomplish two objectives simultaneously: it must define an economically meaningful scope of services that justifies the management fee, and it must do so without crossing the line into clinical control that would transform the MSO into an unlicensed practitioner.
The permissible scope of MSO management services encompasses facilities and equipment provision, information technology infrastructure, billing and revenue cycle management, human resources administration for non-clinical staff, marketing and patient communications, accounting and financial reporting, supply chain and purchasing, and general administrative support. The critical exclusions are clinical staffing decisions, clinical protocols and treatment standards, peer review, credentialing, and any compensation arrangements that tie clinician pay to referral volume or specific clinical decisions. The MSA should contain an explicit clinical independence clause confirming that all clinical judgments are made exclusively by licensed professionals and that the MSO has no authority to direct, override, or influence clinical decisions.
Fair market value documentation for the management fee is the single most important protection against fee splitting and CPOM enforcement risk. The OIG's safe harbor regulations under the Anti-Kickback Statute, while primarily applicable to Medicare and Medicaid arrangements, provide useful guidance on what constitutes a defensible management fee structure. The OIG has indicated that management fees set in advance, not based on referral volume, and consistent with fair market value for the services actually provided are less likely to constitute unlawful remuneration. Annual fair market value opinions from qualified healthcare valuation firms are the standard of care for MSO platforms with significant revenue.
OIG guidance on management services arrangements in the healthcare context, including Advisory Opinion 07-10 and subsequent advisory opinions addressing similar structures, has consistently emphasized three factors in evaluating the legitimacy of a management fee arrangement: whether the fee reflects genuine services rather than a pass-through for referrals, whether the fee is set at fair market value rather than calculated to transfer wealth from the professional entity to the lay entity beyond what the services are worth, and whether the arrangement gives the lay management company any authority over referral decisions that could constitute an inducement to refer. Applying these factors to the MSA during drafting, rather than waiting for a compliance review after the structure is challenged, is the baseline standard for any MSO transaction.
Fee Splitting Analysis: Fixed Percentage vs. Defined Scope, and 2024 California Enforcement Trends
Fee splitting analysis in the DSO and MSO context requires distinguishing between two fundamentally different fee structures. A defined-scope fee structure itemizes the services the MSO provides and assigns a cost to each service category, producing an aggregate management fee that is justified by reference to the specific value delivered. A fixed-percentage structure sets the management fee as a percentage of the professional entity's net collected revenue, without direct reference to the cost of services provided. Both structures are used in the market, but they carry different regulatory risk profiles.
The defined-scope structure is more defensible against fee splitting challenges because the fee is tied to services rather than revenue. If the MSO provides facilities at a defined rent, employs non-clinical staff at documented payroll costs, and provides technology and billing services at documented costs, the aggregate fee can be traced to legitimate expenditures and an appropriate margin. Regulators and plaintiffs' counsel challenging a defined-scope MSA must establish that the stated services were not actually delivered, that the costs were inflated, or that the arrangement was a sham. That is a factually intensive inquiry that is generally harder to sustain than a challenge to a high fixed-percentage structure.
California's enforcement environment has sharpened considerably following several 2024 actions targeting behavioral health MSO arrangements. The California Medical Board and Department of Managed Health Care both took actions against MSO operators whose management fee structures exceeded 40% of net revenue without adequate fair market value support, and in several cases where the MSO was found to have directed clinical staffing and compensation decisions in ways that crossed the CPOM line. The MedMen enforcement trend, beginning with actions in the cannabis sector and extending into healthcare, reflects a broader California posture of treating percentage-based arrangements that substantially transfer professional revenue to lay entities as presumptive violations requiring affirmative justification.
Best practice in any CPOM jurisdiction is to combine a percentage structure with defined-scope documentation and annual fair market value certification. The percentage serves as an operational ceiling on the management fee. The defined-scope documentation establishes what services justify that fee. The annual fair market value certification confirms that the fee remains within the range of what qualified healthcare valuation experts would identify as reasonable compensation for management services of the type and volume actually delivered. This three-layer structure does not guarantee immunity from regulatory challenge, but it provides the most defensible evidentiary foundation if the arrangement is examined.
DSO and MSO Structural Compliance Requires Proactive Legal Architecture
A management services agreement that crosses the CPOM or fee splitting line does not merely create regulatory exposure. It potentially renders the entire economic structure of the transaction unenforceable. Structuring these arrangements correctly before closing is far less expensive than defending them afterward.
Enforcement Cases: Allcare, People v. United Community, and FTC/DOJ Challenges to DSO Roll-Ups
Enforcement actions against DSO and MSO structures provide the most direct guidance on where regulatory lines are drawn. Reviewing the specific fact patterns and holdings of significant enforcement cases is essential for structuring transactions that do not replicate the arrangements that have drawn government attention.
The New York Allcare case in 2011 involved a management company that provided management services to dental practices in New York under arrangements that regulators and ultimately the court found constituted unlicensed practice of dentistry. The critical fact pattern was that the management company exercised substantial control over clinical staffing, treatment planning protocols, and patient scheduling in ways that went beyond legitimate management services. The court's analysis focused on whether the management company was functionally operating the dental practice rather than supporting the dentists who operated it. The case established a fact-intensive control test that New York regulators have applied in subsequent enforcement proceedings against dental and medical management organizations.
California People v. United Community Health Center (2019) addressed a medical MSO that had structured its management fee as a percentage of revenue and whose operational practices demonstrated that the MSO's principals were making clinical staffing and patient care protocol decisions that the Professional Corporation nominally employed the physicians to make. The case resulted in criminal charges under Business and Professions Code Section 2052 for unlicensed practice of medicine, and the court rejected the argument that the management services agreement's express language preserving clinical independence was sufficient to establish actual independence when the operational facts demonstrated the opposite.
FTC and DOJ antitrust enforcement against DSO roll-ups has increased since 2021 as large dental service organizations have consolidated regional markets. The enforcement theory in these cases is that a DSO acquiring independent dental practices in a defined geographic market may substantially lessen competition for dental services, resulting in higher prices and reduced access. The FTC's 2022 action against the Aspen Dental roll-up and subsequent consent orders in the veterinary sector have established that DSO acquisitions are subject to Hart-Scott-Rodino pre-merger notification requirements when thresholds are met, and that market concentration in defined dental or veterinary service markets can trigger a Second Request even for transactions that would not raise antitrust concern in a non-healthcare sector. M&A counsel advising DSO platform companies must incorporate antitrust risk assessment alongside CPOM compliance review as a standard element of pre-transaction due diligence.
Nominee and Friendly Physician Recruitment: Successor Provisions, Death and Disability Triggers, and Tax Implications
Recruiting a licensed clinician to serve as a nominee shareholder in a friendly PC structure requires a careful balance between compensating the nominee adequately for the legal and professional obligations they are assuming and ensuring that the compensation arrangement does not itself create a fee splitting problem. The nominee is providing a legal service by holding shares and agreeing to transfer them, and that service has value that can legitimately be compensated. The compensation must be documented, reasonable, and separate from any clinical compensation the nominee earns for practicing in the professional entity.
Successor provisions in the nominee shareholder agreement should identify the mechanism for finding and installing a replacement nominee when a triggering event occurs. Best practice is to maintain a bench of pre-screened candidates who have undergone background checks, reviewed the nominee agreement, and indicated willingness to serve. Each candidate should sign a conditional acceptance agreement that becomes effective upon the occurrence of a triggering event without requiring a new negotiation. The successor provisions should also address the mechanics of the share transfer: whether the outgoing nominee transfers shares directly to the incoming nominee, whether the professional entity redeems the shares and reissues them to the replacement, and who bears the transaction costs.
Death and disability triggers require coordination between the nominee agreement and the nominee's estate planning. If the nominee dies holding shares in the professional entity, the shares pass to the nominee's estate under state probate law unless the share transfer restriction agreement provides an automatic transfer mechanism that operates outside of probate. An irrevocable assignment of shares in trust, paired with a properly drafted transfer restriction agreement, can accomplish this goal, but the specific mechanism must be reviewed under applicable state corporate and trust law to confirm it is enforceable. Disability triggers are more complex because disability is a condition that can be temporary, partial, or contested, and the nominee agreement must define disability with sufficient specificity to permit the trigger to operate without litigation over whether the condition has been met.
Tax implications of the nominee structure arise in at least three contexts. First, the nominee's compensation for serving in the nominee role is taxable income, and the professional entity's deduction for that compensation must be substantiated by documentation showing it is reasonable. Second, any transfer of shares between nominees may constitute a taxable exchange, and the parties should obtain tax advice on whether the transfer can be structured as a non-recognition transaction under applicable provisions of the Internal Revenue Code. Third, if the professional entity has accumulated earnings or retained profits, the departure of a nominee shareholder may trigger a deemed distribution or other tax event depending on the entity's tax classification. These issues are not hypothetical edge cases: they arise in every nominee transition and must be addressed in the structural documentation before they occur.
MSA Renewal, Termination, Non-Renewal, and Post-Termination Non-Compete Enforceability
The management services agreement that governs the DSO or MSO relationship with the professional entity is typically a long-term contract with an initial term of five to ten years and renewal provisions that extend the term automatically unless one party provides advance notice of non-renewal. The length of the initial term and the renewal mechanism are negotiated with the professional entity at the time the DSO or MSO first establishes the relationship, and they represent a significant portion of the economic value of the arrangement from the MSO's perspective: a long-term MSA with automatic renewal reduces the risk that the professional entity will terminate the relationship and restructure its operations independently.
Termination provisions in the MSA must address both for-cause and convenience termination rights. For-cause termination provisions typically allow either party to terminate if the other materially breaches the agreement and fails to cure within a defined period, or upon the occurrence of specified events such as loss of professional licensure, bankruptcy, or regulatory disqualification. Convenience termination provisions, if included, typically give the MSO the right to terminate with advance notice while giving the professional entity a much more limited or no convenience termination right, reflecting the economic asymmetry of a relationship where the MSO has made capital investments in facilities and equipment that serve the professional entity.
Post-termination non-compete provisions in management services agreements are subject to state law analysis that varies significantly by jurisdiction. California Business and Professions Code Section 16600 renders most non-compete agreements void as a matter of public policy in California, and courts have applied this provision to post-termination restrictions in commercial contracts as well as employment agreements. An MSA non-compete that prohibits the professional entity from entering into a competing management services arrangement after the MSA terminates may be unenforceable in California regardless of its specific terms. New York and Texas apply a reasonableness test to post-termination restrictions in commercial contracts, analyzing the duration, geographic scope, and scope of activities restricted to determine whether the restriction protects a legitimate business interest without unduly restraining trade.
Non-solicitation provisions for clinicians are a related area of risk. An MSA that prohibits the professional entity from soliciting or hiring clinicians who have provided services at MSO-affiliated practices after the MSA terminates may face enforceability challenges under both state non-compete law and healthcare regulatory frameworks that protect clinician mobility in the interest of patient care continuity. California's explicit prohibition on non-competes, as clarified by SB 699 and AB 1076 effective January 2024, applies to all provisions that prevent a former employee or contractor from engaging in a lawful profession, trade, or business. MSO counsel must evaluate whether any non-solicitation or non-compete provision in the MSA will be enforceable in the relevant jurisdiction and build the MSO's structural protections around mechanisms that do not depend on post-termination restrictions that may be voided at a critical moment.
Captive Insurance Structures and Risk Retention Groups in DSO and MSO Platforms
Large DSO and MSO platforms have increasingly adopted captive insurance structures as a mechanism for managing professional liability risk, reducing commercial insurance premium costs, and capturing underwriting profit within the enterprise. A captive insurance company is an entity formed by and for the benefit of its parent or affiliated group to insure the risks of the parent and affiliates. In the DSO context, the captive may insure the professional entities affiliated with the platform against dental or medical malpractice claims, with the captive's premiums funded by the professional entities and reinsurance placed in the commercial market for catastrophic layers.
The regulatory framework for captive insurance requires that the captive be licensed or authorized in the jurisdiction where it is domiciled, that it maintain adequate reserves to pay expected claims, and that the premium rates charged to the professional entities reflect arm's-length pricing that would apply in a commercial insurance market. The risk retention group, a specific form of captive authorized under the federal Liability Risk Retention Act of 1986, allows professional liability groups to form a federally authorized insurer that can write coverage in any state without obtaining a license in each state, subject to registration and financial reporting requirements in each state where it operates.
The intersection of captive insurance structure and CPOM doctrine creates a specific compliance consideration. If the MSO, rather than the professional entities, owns or controls the captive insurance company, the captive's insurance relationship with the professional entities may be analyzed as an additional financial arrangement between the lay entity and the professional practices that is subject to fee splitting and CPOM scrutiny. Regulators examining MSO arrangements have asked whether captive insurance premiums represent fair market value coverage or whether the captive structure is being used to transfer additional revenue from the professional entity to the lay MSO in a form that avoids scrutiny as a management fee.
Due diligence on a DSO platform that operates a captive insurance structure should evaluate the captive's domicile and regulatory standing, the actuarial basis for premium rates charged to professional entities, the claims handling history and reserve adequacy, any prior regulatory examinations or notices from the domicile jurisdiction, and the ownership structure of the captive relative to the MSO and professional entities. In an acquisition of the platform, the buyer must determine whether the captive will be included in the transaction, whether the professional entities will continue to receive coverage from the captive post-closing, and whether any change in the captive's ownership or management will require regulatory notification or approval in the domicile state or in the states where the professional entities are located.
Stock Pledge and Buy-Sell Arrangements, 83(b) Elections, and Economic Interest Documentation
The friendly PC structure creates a situation in which the nominee holds legal title to shares that carry an economic interest the MSO is effectively entitled to. Documenting this economic interest in a legally sound manner, while keeping the documentary trail consistent with CPOM compliance, is one of the more technically demanding aspects of DSO and MSO legal work. The mechanisms for accomplishing this goal include stock pledge agreements, economic interest assignment agreements, and option agreements, each with distinct legal characteristics and tax implications.
A stock pledge agreement grants the MSO or its designee a security interest in the nominee's shares in the professional entity, perfected under Article 9 of the Uniform Commercial Code to the extent applicable to equity interests in professional corporations. The pledge secures the nominee's performance of obligations under the nominee shareholder agreement. Upon the nominee's breach or failure to perform, the pledgee can foreclose on the shares and cause them to be transferred to a replacement nominee. The pledge agreement does not transfer economic interest directly but creates an enforcement mechanism that gives the MSO practical control over the shares in the event of nominee non-compliance.
An 83(b) election under Internal Revenue Code Section 83(b) is relevant when a nominee receives shares or equity interests that are subject to a substantial risk of forfeiture, such as vesting conditions or performance conditions. By making an 83(b) election within 30 days of receiving the restricted property, the recipient elects to include the value of the property in gross income at the time of receipt rather than at vesting, locking in potentially lower value for tax purposes. In the friendly PC context, if the nominee receives shares subject to transfer restrictions and forfeiture conditions under the stock transfer restriction agreement, the nominee may have an interest in making an 83(b) election if the shares have de minimis value at issuance. The election must be filed within the strict 30-day deadline, and failure to elect means ordinary income recognition at full vesting value.
The economic interest documentation package for a well-structured friendly PC arrangement typically includes: the nominee shareholder agreement establishing the nature of the nominee's role and obligations; the stock transfer restriction agreement establishing the forfeiture and transfer conditions; a separate economic interest assignment agreement or profit participation agreement that documents the MSO's entitlement to distributions or profits from the professional entity; and any applicable pledge or security agreement. This package must be reviewed in its entirety to confirm that the economic reality it creates is consistent with the regulatory posture asserted in the management services agreement, specifically that the nominee holds genuine equity in the professional entity and that the MSO's economic participation is derived from its management services relationship rather than from a disguised ownership interest.
Structuring DSO and MSO Transactions Requires Healthcare M&A Counsel
The friendly PC model, MSO management services agreements, and CPOM compliance cannot be addressed through general M&A contract forms. Every element of the structure requires healthcare regulatory expertise applied alongside transaction mechanics. Acquisition Stars works on these structures from letter of intent through closing.
Private Equity Structuring: Continuation Funds, Management Rollover, and Management Incentive Plans in DSO Platforms
Private equity investment in DSO and MSO platforms operates through the lay management company, because CPOM doctrine precludes direct equity ownership of the professional entities in most states. The PE sponsor acquires equity in the MSO holding company, which in turn holds the management services agreements with the affiliated professional entities. The sponsor's return depends on the aggregate management fee cash flows from the professional entity network, the platform's growth through new practice additions, and the multiple expansion achievable at exit through a sale to a strategic buyer or a larger PE platform.
Continuation fund structures are increasingly used by PE sponsors who have held DSO platform investments beyond the traditional five-to-seven-year fund life but believe additional value creation opportunities remain. A continuation fund allows the sponsor to transfer the platform investment from the original fund into a new vehicle that can hold the asset for an additional period. Limited partners in the original fund are offered the option to roll their interest into the continuation fund or to receive liquidity at a fund-to-fund transaction price. The continuation fund structure requires that the transfer be priced at fair market value, that LP consent requirements in the original fund's limited partnership agreement be satisfied, and that any regulatory approvals required for a change of control at the MSO or platform level be obtained before the transfer.
Management rollover is a standard feature of DSO platform acquisitions where the incumbent management team has equity in the existing platform and is expected to continue operating the business post-closing. The rollover typically involves the management team contributing a portion of their transaction proceeds into equity of the new acquisition vehicle rather than taking full cash at closing. The rollover creates alignment between the management team and the new sponsor, and it is often structured to provide the management team with favorable tax treatment under Section 351 or other non-recognition provisions if the rollover qualifies as a contribution of property to a controlled entity.
Management incentive plans in DSO platforms are structured as profits interests in the MSO holding company or as options on equity in the holding company, rather than as equity in the professional entities. A profits interest in the holding company entitles the holder to a share of future appreciation above the value of the holding company at the time the profits interest is granted, without giving the holder a share of the existing capital. A properly structured profits interest qualifies for capital gains treatment on appreciation, and it avoids immediate income inclusion at grant because the holder receives no share of value that already exists. MIP design in DSO platforms must account for the bifurcated structure: because the professional entities are not owned by the holding company, the MIP must be designed to capture economic value from the MSA revenue streams and from the capital appreciation of the holding company's MSO operations, without creating any arrangement that gives the MIP participants a direct or indirect interest in the professional entities.
Reps and Warranties, CPOM Compliance Representations, and Special Indemnification Structures
Representations and warranties in a DSO or MSO acquisition must address the specific legal risks of the healthcare management company structure in addition to the standard representations applicable to any commercial transaction. Generic employment, contracts, and compliance representations do not capture the specific categories of CPOM, fee splitting, and professional licensure exposure that are the primary regulatory risks in these transactions. Counsel on both sides of the transaction should work from a healthcare-specific representation framework rather than a general M&A template.
The CPOM compliance representation should confirm: that the seller has obtained qualified healthcare legal opinions in each state where the platform operates regarding the compliance of its MSO structure with applicable CPOM and fee splitting prohibitions; that each management services agreement has been reviewed and is structured to comply with applicable state law; that management fees under all MSAs are supported by independent fair market value analyses; that no governmental authority has issued a written notice, citation, or investigation notice related to CPOM compliance, fee splitting, or unlicensed practice in any jurisdiction; and that the nominee shareholder agreements and stock transfer restriction agreements are in full force and enforceable under applicable state law. The survival period for these representations should extend to the applicable statutes of limitations for state enforcement actions, which in the healthcare context commonly run three to five years.
Special indemnification for CPOM and regulatory compliance exposure sits outside the general indemnification cap in well-negotiated DSO purchase agreements. The general indemnification cap in a middle-market healthcare platform transaction typically ranges from 15% to 25% of the purchase price, which may be inadequate to cover the full exposure from a significant CPOM enforcement action or regulatory proceeding. The special indemnification for CPOM-related losses should operate dollar-for-dollar from a dedicated escrow, cover civil and criminal fines, penalties, disgorgement, and attorneys fees, and extend for a period sufficient to capture enforcement actions that are initiated post-closing based on pre-closing conduct.
Representations and warranties insurance coverage for DSO and MSO transactions presents specific underwriting challenges. RWI underwriters scrutinize the CPOM compliance framework carefully during the underwriting process, and they will typically require representation from the seller's healthcare regulatory counsel that the MSO structure is compliant before agreeing to insure CPOM-related representations. Known compliance gaps or pending regulatory inquiries are categorically excluded from coverage, and underwriters have become more sophisticated about requesting state-by-state CPOM opinions, MSA fair market value certifications, and nominee agreement documentation as conditions of binding. Buyers who intend to rely on RWI coverage for CPOM representations should engage with underwriters early and ensure that the seller's disclosure materials support the representations being made, because an exclusion negotiated at binding cannot be removed post-closing. Contact Alex Lubyansky at Acquisition Stars at 248-266-2790 to discuss structuring CPOM compliance representations and indemnification in your DSO or MSO transaction.
Frequently Asked Questions
Are management fees owed to an MSO enforceable if the underlying MSA is found to violate the corporate practice of medicine doctrine?
The enforceability of MSO management fees when the underlying management services agreement is challenged under corporate practice of medicine doctrine depends on how the contract is structured and which state's law governs. Courts in California and New York have found that where an MSA effectively transfers operational control of the professional entity to the lay management company, the agreement may be treated as an unlicensed practice arrangement rather than a legitimate management contract, and fees paid or owed under it may be unenforceable or subject to recovery as unjust enrichment. The key structural distinction is whether the MSA limits the MSO to purely administrative, operational, and non-clinical support functions or whether it grants the MSO authority over clinical staffing, patient care protocols, or clinical compensation that the CPOM doctrine reserves to licensed professionals. Agreements drafted with defensible scope limitations, fair market value fee documentation, and explicit carve-outs for clinical decision authority are substantially more likely to survive enforcement challenges than those structured to give the MSO effective clinical control under the guise of management services.
What happens if a friendly physician nominee refuses to execute a stock transfer or resigns without triggering the succession mechanism?
The failure of a friendly physician nominee to cooperate with a stock transfer or succession mechanism is one of the central structural risks in the friendly PC model and must be addressed through multiple legal layers rather than relying on a single contract. A well-drafted nominee shareholder agreement should include irrevocable proxy provisions granting the MSO or its designee the authority to vote the nominee's shares on all matters, a power of attorney authorizing execution of stock transfer documents on the nominee's behalf, a pre-signed undated stock transfer agreement held in escrow, and a buy-sell obligation triggered by defined events including resignation, death, disability, loss of licensure, and breach of the nominee agreement. Even with these protections, enforcement requires that the nominee's estate or successor cooperate in the transfer, and state law on irrevocable proxies and powers of attorney varies. California, for example, has limitations on certain irrevocable proxy structures under Corporations Code Section 705 that must be navigated carefully. The succession plan should designate a pool of pre-screened replacement nominees who have signed conditional nominee agreements, so that a new nominee can step into the structure within days of a vacancy rather than requiring a new recruitment cycle under time pressure.
What is a defensible fair market value range for MSO management fees as a percentage of professional entity revenue?
There is no universally accepted percentage range for MSO management fees that constitutes per se fair market value. The appropriate fee must be established through an independent fair market value analysis that considers the specific services provided, the local market for comparable management services, the complexity of the operations managed, and the capital investment the MSO has made in facilities, equipment, and infrastructure leased or licensed to the professional entity. In practice, management fee arrangements in the dental and medical DSO context have ranged from 15% to 40% of net collected revenue, with the higher end of the range applying in arrangements where the MSO provides substantial capital, real estate, technology, and staffing infrastructure. The OIG has not established a safe harbor percentage for management fees, and any percentage-based structure requires support from a formal valuation opinion by a qualified healthcare valuation firm. Annual recertification of fair market value is advisable, particularly as revenue grows, because a fee that was fair market value in year one may appear excessive if it grows mechanically with revenue without a corresponding increase in services delivered.
Which states impose the strictest corporate practice of medicine and dentistry prohibitions, and which are most permissive for lay ownership structures?
The strictest CPOM jurisdictions include California, New York, Illinois, Texas, New Jersey, and Oregon, each of which maintains categorical prohibitions on lay entity ownership of medical or dental practices, with robust enforcement mechanisms and case law interpreting the doctrine broadly. California's CPOM doctrine is codified in the Medical Practice Act and Business and Professions Code, and People v. United Community Health Center and related decisions have demonstrated active enforcement against both civil and criminal violators. New York has enforced the doctrine through the Allcare case and related administrative actions, and Oregon has been particularly aggressive in the veterinary context. The most permissive jurisdictions for lay ownership structures include Arizona, which allows lay ownership of medical practices under certain structural conditions, and Florida, Michigan, Ohio, and Colorado, which permit broader MSO arrangements and in some cases allow lay entities to hold equity in professional entities under specific licensing frameworks. Several states, including Washington and Georgia, occupy a hybrid position: they do not prohibit lay ownership categorically but impose significant limitations on the scope of lay control and require robust clinical independence protections. Any multi-state DSO must map each jurisdiction separately because a structure that is compliant in one state may violate another state's doctrine.
What CPOM compliance representations are adequate in a purchase agreement for a DSO or MSO acquisition?
Adequate CPOM compliance representations in a DSO or MSO acquisition purchase agreement should cover: (1) that the professional entities are duly licensed and in good standing in every state where they operate; (2) that no lay entity holds an ownership interest in any professional entity in violation of applicable CPOM doctrine; (3) that each management services agreement has been reviewed by qualified healthcare counsel in each applicable jurisdiction and is structured to comply with applicable fee splitting and CPOM prohibitions; (4) that management fees under all MSAs have been supported by independent fair market value analyses conducted within the prior 24 months; (5) that no governmental authority has issued a notice, citation, or investigation related to CPOM compliance in any jurisdiction where the target operates; (6) that each nominee shareholder agreement and stock transfer restriction agreement is in full force and is enforceable under applicable state law; and (7) that the target has not received legal advice that any component of its MSO structure fails to comply with applicable state law. A special CPOM indemnification should sit outside the general indemnification cap and provide dollar-for-dollar coverage for losses arising from any breach of these representations, with a survival period extending to the applicable state statutes of limitations for regulatory enforcement actions, which in healthcare contexts can run three to five years.
What percentage-based management fee structures raise fee splitting red flags, and how should defined-scope arrangements be structured instead?
Fee splitting prohibitions in medical and dental practice statutes are typically triggered when a licensed professional shares professional fees with an unlicensed entity as compensation for referrals or as a condition of practice operation, rather than as payment for legitimate services. A management fee structured as a fixed percentage of revenue, particularly at a high percentage, creates fee splitting risk because it ties the unlicensed entity's compensation directly to the volume of professional services rendered, which regulators in California, New York, and Texas have treated as a proxy for referral compensation. The safer structural approach is to define the MSO's fee in terms of the specific services delivered: facilities lease, equipment lease, staffing services, billing and collection, technology platform access, and administrative support each assigned a defined cost, with the aggregate fee subject to annual fair market value certification. If a percentage structure is used for operational simplicity, it should be capped at a level that does not exceed the independently certified fair market value of services, adjusted annually, and documented through a formal valuation opinion. California's 2024 enforcement actions targeting MSO arrangements in the behavioral health sector have demonstrated that percentage-based structures exceeding 40% of net revenue draw heightened scrutiny regardless of how the fee is labeled in the contract.
What structural risks do private equity sponsors face when acquiring DSO platforms in CPOM jurisdictions?
Private equity sponsors acquiring DSO platforms in CPOM jurisdictions face three categories of structural risk that do not exist in standard service business acquisitions. First, the sponsor cannot hold direct equity in the professional entities, which means the sponsor's economic returns depend entirely on the enforceability of the MSA and the cooperation of the friendly PC structure. If the MSA is found unenforceable, the sponsor loses its mechanism for extracting value from the clinical operations. Second, the nominee shareholder structure creates a layer of human dependency that introduces succession risk, nominee defection risk, and regulatory scrutiny risk that is difficult to fully mitigate through contract. Third, post-closing regulatory enforcement or license revocation at the state level can suspend clinical operations without giving the sponsor the legal standing to respond directly, because the licensed professionals, not the sponsor, hold the permits that allow the business to operate. These risks are compounded in roll-up strategies where dozens or hundreds of friendly PC structures must be maintained across multiple states, each with its own regulatory requirements. Sponsors entering these markets should obtain state-by-state CPOM legal opinions before closing, maintain a legal compliance calendar for each jurisdiction, and structure their management incentive plans to align the licensed professionals' interests with the MSO's long-term compliance obligations.
What post-sale Department of Health audit triggers are common in DSO and MSO transactions, and how should sellers prepare?
State Department of Health and professional licensing board audit triggers that commonly arise after a DSO or MSO acquisition include: change of ownership notifications required by state law or accreditation standards, which automatically initiate a compliance review in many jurisdictions; increased billing volume or sudden changes in billing patterns that trigger Medicaid or Medicare post-payment audits; employee or patient complaints filed with licensing boards after a change in management; press coverage or regulatory alerts about the private equity acquirer in other markets; and cross-referrals from other state agencies that have received change of ownership notifications for the same entity. Sellers preparing for post-sale audit exposure should ensure that all clinical licensure files, DEA registrations, state controlled substance permits, and accreditation certificates are current and accessible. The practice's compliance program documentation, including policies and procedures, training records, and any prior audit correspondence, should be organized in a compliance data room that can be produced to regulators on short notice. Prior audit findings that were resolved should be documented with evidence of remediation, because a prior finding with no documented remediation is more harmful than the original deficiency if discovered in a post-sale audit.
Related Resources
Veterinary and Dental DSO M&A Legal Guide
The complete legal framework for M&A transactions involving veterinary and dental service organizations, from diligence through closing and integration.
RelatedDEA and State License Transfer in Veterinary and Dental M&A
How DEA registration transfer, state controlled substance permits, and professional licensure requirements affect deal structure and closing timelines in veterinary and dental acquisitions.
RelatedClinical Integration and Associate Employment Agreements in Healthcare M&A
Structuring associate physician, dentist, and veterinarian employment and independent contractor agreements for DSO and MSO platforms through acquisition and post-closing integration.
The DSO and MSO model is a sophisticated legal architecture that creates real value for both the capital providers who back these platforms and the clinicians who participate in them. That value is entirely dependent on the legal integrity of the structure. A management services agreement that crosses the CPOM line, a nominee arrangement that cannot withstand regulatory scrutiny, or a management fee that cannot be supported by fair market value documentation can unravel the entire economic framework of a platform that took years and significant capital to build.
Transactions that get this right are those where qualified healthcare M&A counsel is engaged from the letter of intent stage, conducts state-by-state CPOM analysis as a mandatory diligence item, and builds the compliance framework into the purchase agreement's representations, covenants, and indemnification structure rather than leaving it to post-closing remediation. Acquisition Stars advises buyers, sellers, and platform operators on the full spectrum of DSO and MSO legal issues, from structural design through transaction execution and regulatory compliance. Reach Alex Lubyansky directly at 248-266-2790 or submit your transaction details through the form below.